摘要
Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS)represents an innovative surgical technique used for the treatment of large hepatic lesions at high risk for post-resection liver failure due to a small future liver remnant.The most significant amount of literature concerns the use of ALPPS for the treatment of hepatocellular carcinoma(HCC),cholangiocarcinoma(CCC),and colorectal liver metastases(CRLM).On the opposite,few is known about the role of ALPPS for the treatment of uncommon liver pathologies.The objective of the present study was to evaluate the current literature on this topic.A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)guidelines.Eligible articles published up to February 2020 were included using the MEDLINE,Scopus,and Cochrane databases.Among the 486 articles screened,45 papers met the inclusion criteria,with 136 described cases of ALPPS for rare indications.These 136 cases were reported in 18 different countries.Only in two countries,namely Germany and Brazil,more than ten cases were observed.As for the ALPPS indications,we reported 41(30.1%)cases of neuroendocrine tumor(NET)metastases,followed by 27(19.9%)cases of gallbladder cancer(GBC),nine(6.6%)pediatric cases,six(4.4%)gastrointestinal stromal tumors,six(4.4%)adult cases of benign primary liver disease,four(2.9%)adult cases of malignant primary liver disease,and 43(31.6%)adult cases of malignant secondary liver disease.According to the International ALPPS Registry data,less than 10%of the ALPPS procedures have been performed for the treatment of uncommon liver pathologies.NET and GBC are the unique pathologies with acceptable numerosity.ALPPS for NET appears to be a safe procedure,with satisfactory long-term results.On the opposite,the results observed for the treatment of GBC are poor.However,these data should be considered with caution.The rationale for treating benign pathologies with ALPPS appears to be weak.No definitive response should be given for all the other pathologies.Multicenter studies are needed with the intent to clarify the potentially beneficial effect of ALPPS for their treatment.
